Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect Study of Linrodostat in Healthy Participants
NCT03312426Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2017
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of linrodostat in solid tumor (4 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration following administration with a high-fat meal up to 21 days, Area under the plasma concentration-time curve from time zero to 168 hours following administration with a high-fat meal and 2 more. Started Oct 2017; status: completed.
02
Drugs
linrodostat
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03312426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03312426.